We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (“REIT”) earnings release this morning:
An In-line FFO
Ventas came out with second-quarter 2016 normalized funds from operations (“FFO”) per share of $1.04, in-line with the Zacks Consensus Estimate. Important quarterly highlights were robust performance of the high-quality healthcare and senior living properties and accretive acquisitions.
How Was the Estimate Revision Trend?
Ventas has a decent earnings surprise history. Before posting an in-line Q2 results, the company delivered positive surprises in all the trailing four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 2.1% in the trailing four quarters.
Revenue Came In Higher Than Expected
Ventas posted revenues of $848.4 million, which beat the Zacks Consensus Estimate of $837 million. Further, it compared favorably with the year-ago number of $811.9 million.
Key Developments to Note
Ventas revised its 2016 normalized FFO per share outlook in the range of $4.05 – $4.13, denoting expected growth of 3–5% from 2015 on a comparable basis. However, this marks a downward revision from the earlier range of $4.07 – $4.15, due to the dilutive impact of pre-funding a part of the Wexford acquisition with equity and additional deleveraging.
Like earlier predication, the company anticipates same-store cash net operating income growth of 2–3% in 2016, from the previous guidance of 1.5–3%. Further, Ventas estimates 2016 dispositions of $500 million and intends to use the net proceeds from disposition for reinvestment into acquisition and debt repayment.
Ventas has a Zacks Rank #2 (Buy). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.
Check back later for our full write up on this VTR earnings report later!
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Ventas' (VTR) Q2 FFO In-Line, Revenues Beat Estimates
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (“REIT”) earnings release this morning:
An In-line FFO
Ventas came out with second-quarter 2016 normalized funds from operations (“FFO”) per share of $1.04, in-line with the Zacks Consensus Estimate.
Important quarterly highlights were robust performance of the high-quality healthcare and senior living properties and accretive acquisitions.
How Was the Estimate Revision Trend?
Ventas has a decent earnings surprise history. Before posting an in-line Q2 results, the company delivered positive surprises in all the trailing four quarters. Overall, the company surpassed the Zacks Consensus Estimate by an average of 2.1% in the trailing four quarters.
Revenue Came In Higher Than Expected
Ventas posted revenues of $848.4 million, which beat the Zacks Consensus Estimate of $837 million. Further, it compared favorably with the year-ago number of $811.9 million.
Key Developments to Note
Ventas revised its 2016 normalized FFO per share outlook in the range of $4.05 – $4.13, denoting expected growth of 3–5% from 2015 on a comparable basis. However, this marks a downward revision from the earlier range of $4.07 – $4.15, due to the dilutive impact of pre-funding a part of the Wexford acquisition with equity and additional deleveraging.
Like earlier predication, the company anticipates same-store cash net operating income growth of 2–3% in 2016, from the previous guidance of 1.5–3%. Further, Ventas estimates 2016 dispositions of $500 million and intends to use the net proceeds from disposition for reinvestment into acquisition and debt repayment.
VENTAS INC Price and EPS Surprise
VENTAS INC Price and EPS Surprise | VENTAS INC Quote
What Zacks Rank Says
Ventas has a Zacks Rank #2 (Buy). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.
Check back later for our full write up on this VTR earnings report later!
Note: All EPS numbers presented in this write-up represent funds from operations (“FFO”) per share. FFO, a widely used metric to gauge the performance of REITs, is obtained after adding depreciation and amortization and other non-cash expenses to net income.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>